Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.

Diabetes Obes Metab. 2022;24:289-295

Webb J, Mount J, von Arx LB, Rachman J, Spanopoulos D, Wood R, Tritton T, Massey O, Idris I